Coronavirus

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The country says one city hospital’s data shows a decrease in severity and mortality during this latest variant's outbreak.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Angela Rasmussen, PhD, and Donald Alcendor, PhD have a conversation on the recent expansion of COVID-19 booster shot usage in eligible populations.

Immigrant communities may be more hesitant to disclose personal health information due to fears of bullying or deportation, a new study finds.

Key opinion leaders debate on the necessity of COVID-19 booster shots.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

COVID-19 patients who underwent prior weight-loss surgery were significantly less likely to experience severe disease outcomes.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

The oral antiviral therapy proceeds the first indication for the drug class by just a day; the US will now have multiple pills to treat COVID-19.

This is the first pill to treat COVID-19 in trying to prevent progression to severe disease and possible hospitalization.

COVID-19 patients were not at increased risk of Clostridium difficile infection. However, those already infected with C diff were more likely to experience severe outcomes.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Here’s where you should sit on the bus to avoid COVID-19 droplets.

Less than 3 weeks after it was first reported, Omicron becomes the dominant COVID-19 variant in the US.

In the age of COVID-19, providers caring for patients with emerging diseases do not rely entirely on clinical guidelines, but also consult online resources that are updated more frequently. This needed integration helps providers adapt to the best-available evidence into bedside care when guidance is lacking.

Respiratory syncytial virus (RSV) cases decreased due to COVID-19 precautions. Investigators estimated the rate and timing of RSV resurgence over the next few years.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.

Will this winter bring the feared twindemic of SARS-CoV-2 and influenza, or will another common infection reemerge?

Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.

A study of patients hospitalized with COVID-19 pneumonia found namilumab, but not infliximab, significantly reduced inflammation and CRP concentration.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

Children in the United States will be able to avoid potentially millions of hours of at-home quarantining under a testing program unveiled by the CDC today.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.

A clinical trial of 8 sub-Saharan African countries will be the first to study the efficacy of mRNA COVID-19 vaccination in people living with HIV.